Skip to content

Caffeine, exercise physiology, and time-trial performance: no effect of ADORA2A or CYP1A2 genotypes.

PMID 33170731 (2021): caffeine — Time-trial performance, Time to exhaustion (study note for endurance athletes).

Last updated/Feb 23, 2026, 10:34 PM

Study note • PMID 33170731

Caffeine, exercise physiology, and time-trial performance: no effect of ADORA2A or CYP1A2 genotypes.

Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme2021 • DOI 10.1139/apnm-2020-0551
Evidence C69/100
Action 2: Consider

Worth trying if it fits your goal and context.

ELI5

In plain language

The aim of this study was to investigate the influence of ADORA2A and CYP1A2 genotypes on the physiological and ergogenic effects of caffeine. (randomized trial; cyclists).

The abstract reports an association involving Time-trial performance (not necessarily causation). Treat this as a signal, not a guarantee; confirm methods and context in the full paper.

Takeaways

What the abstract suggests

  • Study question: The aim of this study was to investigate the influence of ADORA2A and CYP1A2 genotypes on the physiological and ergogenic effects of caffeine.
  • The abstract reports an association involving Time-trial performance (not necessarily causation).
  • Population: cyclists.
  • Protocol cues (title/abstract): 5 mg • 1 h • 30 min • 1.8 min • 2.3 min.

Protocol

Protocol (as reported)

  • Intervention/exposure: caffeine (vs placebo).
  • Dose/time/duration cues in abstract/title: 5 mg • 1 h • 30 min • 1.8 min • 2.3 min.
  • Outcomes: Time-trial performance, Time to exhaustion.
  • Replication note: abstracts often omit adherence and timing; confirm details before changing training or supplementation.

Fit

Who it helps, and who should skip it

Who it helps

  • Athletes similar to the study population (cyclists) working on supplements.
  • Athletes who can measure Time-trial performance, Time to exhaustion with a repeatable workout or time-trial effort.

Who should skip

  • If you have symptoms or conditions that make the intervention risky, get professional guidance.
  • If you’re near race day and can’t safely test, defer the experiment.

Methods

What the study actually did

  • Design: randomized trial (double-blind, placebo-controlled).
  • Population: cyclists.
  • Comparator: placebo.
  • Outcomes measured: Time-trial performance, Time to exhaustion.
  • Protocol cues mentioned: 5 mg • 1 h • 30 min • 1.8 min • 2.3 min.
  • Source: PubMed PMID 33170731 (2021) — Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.

Results excerpt

What the abstract reports

Nonetheless, there were no supplement x genotype interactions.

Note: excerpts are short; for full context, read the paper.

Limits

Limitations & bias

  • Abstract-only summaries can miss critical details (population, protocol, adherence, and context).
  • Single studies often don’t generalize to your event, history, and training load; treat results as a starting point.
  • If your context differs (elite vs recreational; cycling vs running), adjust expectations and be conservative.
  • This is performance information, not medical advice.

Coaching beta

Get a plan that adapts to your life.

Join the 26weeks.ai TestFlight beta for adaptive coaching, recovery-aware adjustments, and race-week reminders.

Keep going

Sources